Kunz C, Hofmann H, Frisch-Niggemeyer W
Wien Klin Wochenschr. 1984 Feb 17;96(4):158-61.
In a field study conducted with the Hepatitis B vaccine HB-Vax 375 persons were vaccinated and the sera were assayed for the formation of HBs antibodies 1 to 3 months after completing the three-dose schedule. Seroconversion was demonstrated in 94.7% of the subjects. Immune response was poorer after 40 years of age as compared with younger age groups. The vaccine was very well tolerated and induced hardly any side effects. 49 persons who had received 3 of the 4 doses suggested for vaccination with Hevac B responded in 86% of cases with the formation of antibodies. Patients undergoing dialysis developed antibodies in 48% of cases after the third dose and in 77% after the fourth dose, the seroconversion rate thus being considerably lower than in healthy persons.
在一项针对乙肝疫苗HB - Vax开展的现场研究中，375人接种了疫苗，并在完成三剂接种程序后的1至3个月检测血清中乙肝表面抗体的形成情况。94.7%的受试者出现了血清转化。与较年轻年龄组相比，40岁以上人群的免疫反应较差。该疫苗耐受性良好，几乎未引发任何副作用。49名接种了Hevac B建议的4剂次中的3剂次的人，86%的人产生了抗体。接受透析的患者在第三剂后48%的病例中产生了抗体，第四剂后77%的病例产生了抗体，因此其血清转化率明显低于健康人群。
